Mizuho Securities analyst Ann Hynes assigned a Hold rating to Walgreens Boots Alliance (WBA – Research Report) on April 8 and set a price target of $49.00. The company’s shares closed last Monday at $44.43, close to its 52-week low of $42.90.
According to TipRanks.com, Hynes is a 5-star analyst with an average return of 13.1% and a 68.3% success rate. Hynes covers the Healthcare sector, focusing on stocks such as AmerisourceBergen, Quest Diagnostics, and Molina Healthcare.
Currently, the analyst consensus on Walgreens Boots Alliance is a Hold with an average price target of $48.63, implying a 6.9% upside from current levels. In a report issued on April 1, Robert W. Baird also downgraded the stock to Hold with a $51.00 price target.
See today’s best-performing stocks on TipRanks >>
Walgreens Boots Alliance’s market cap is currently $39.21B and has a P/E ratio of 6.27.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Retail pharmacy leader Walgreens Boots Alliance (NASDAQ:WBA) operates through its namesake brand Walgreens in the U.S. and Boots in the U.K. In addition, it owns retail and business brands including the No7 Beauty Company, Duane Reade, Ahumada in Chile, and Benavides in Mexico. The company also targets equity investments in healthcare, pharmacy, and retail and has a presence in over 25 countries with more than 450,000 employees.
Read More on WBA:
- Leerink Partners Thinks Genocea Biosciences’ Stock is Going to Recover
- Leerink Partners Reaffirms Their Buy Rating on Cogent Biosciences (COGT)
- Affimed (AFMD) Initiated with a Buy at Leerink Partners
- Leerink Partners Keeps Their Buy Rating on Seagen (SGEN)
- Leerink Partners Remains a Buy on Bicycle Therapeutics (BCYC)
